Calithera Biosciences (NASDAQ:CALA) Earns Hold Rating from Analysts at StockNews.com

Posted by on Jan 4th, 2025

StockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALA – Free Report) in a research report sent to investors on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Calithera Biosciences Stock Up 200.0 %

CALA opened at $0.00 on Friday. Calithera Biosciences has a 52 week low of $0.00 and a 52 week high of $0.12.

Calithera Biosciences Company Profile

(Get Free Report)

Calithera Biosciences, Inc operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc was incorporated in 2010 and is headquartered in South San Francisco, California.

Read More

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.